Who received FDA approval for Skinvive?

Allergan Aesthetics, an AbbVie (ABBV) company, received the approval.

When was the FDA approval announced?

The announcement was made on June 16, 2026.

Has AbbVie announced the price of Skinvive?

No, AbbVie has not yet disclosed pricing details.

AbbVie's Skinvive by Juvederm Gets FDA Nod for Neck Lines

Allergan Aesthetics, an AbbVie (ABBV) company, received FDA approval for Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults aged 21 and older.

June 22, 2026

2 min read

Source: Insider Monkey

Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE:ABBV), announced on June 16, 2026, that the U.S. Food and Drug Administration (FDA) has approved Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over 21.

The Product

Skinvive by Juvederm is a dermal filler designed to improve the appearance of neck lines. It expands AbbVie's Juvederm portfolio, which already includes products for wrinkles and lip augmentation.

Pricing and Availability

AbbVie has not yet disclosed pricing or commercial availability details for Skinvive.

Competition

The neck line treatment market includes competitors such as Botox (also from Allergan) and products from Galderma and Merz. Skinvive adds a new option to this segment.

Potential Impact on AbbVie

Skinvive is expected to strengthen AbbVie's position in the growing medical aesthetics market. If priced competitively and adopted widely, it could boost revenue for the Allergan Aesthetics segment.

Frequently Asked Questions

Skinvive by Juvederm is an FDA-approved dermal filler to reduce neck lines and improve neck appearance in adults over 21.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.